US Earnings Financial Results SEC Filings — September 17, 2026

17-09-2026

5E Advanced Materials, Inc. filed its 10-K for the fiscal year ended June 30, 2026, reporting a net loss of $42.9M, widening 36% from a $31.6M loss in FY2025. While operating expenses were nearly flat (down 1% to $43.3M), the company recorded a $1.6M impairment expense and saw a sharp decline in non-operating income due to the absence of prior-year gains on debt extinguishment and derivatives. On a positive note, cash and cash equivalents surged to $19.5M from $3.8M, driven by $42.3M in financing activities, primarily from equity issuance.

• · Net loss per common share (basic and diluted) improved to ($1.43) in FY2026 from ($3.95) in FY2025, despite the larger net loss, due to a significant increase in weighted average shares outstanding from 7,996 to 29,974.
• · Total assets decreased 4% to $68.0M from $70.7M, primarily due to a decline in property, plant and equipment (net) from $53.7M to $34.4M.
• · Total liabilities decreased 48% to $3.9M from $7.5M, driven by a reduction in accounts payable and accrued liabilities from $6.4M to $2.8M and the elimination of long-term debt.
• · Stockholders' equity increased slightly to $64.1M from $63.2M, supported by $42.4M in net proceeds from equity and warrant issuances, offset by the $42.9M net loss.
• · Project expenses increased 3% to $5.2M from $5.0M, while small-scale facility operating costs decreased 29% to $3.1M from $4.3M.
• · Interest expense dropped sharply to $18K from $6.5M, reflecting the extinguishment of convertible notes.
• · Cash used in investing activities increased 287% to $7.6M, primarily due to $6.6M in property, plant and equipment additions.

17-09-2026

Greenlit Ventures Inc. filed its 10-Q for the quarter ended March 31, 2026, reporting a net loss of $18,496, an 11% improvement from the $20,703 loss in the same quarter last year. However, the company has zero cash and total assets, with total liabilities of $255,942 and a working capital deficiency that worsened 32% to $58,218. The company remains dependent on external financing and has no revenue-generating operations.

• · Zero cash and zero total assets at both March 31, 2026 and December 31, 2025.
• · Convertible note payable increased from $193,448 to $197,724 during the quarter.
• · Accumulated deficit grew from $771,661 to $790,157.
• · Stockholders' deficit worsened from $237,446 to $255,942.
• · Operating expenses paid by unaffiliated parties dropped 55% from $9,426 to $4,276.
• · No cash used in or provided by operating activities; net cash change was zero.

17-09-2026

Vogenx, Inc. reported a net loss of $384,430 for Q2 2026 (ending June 30, 2026), widening from a $294,797 loss in Q2 2025, driven by higher operating expenses and a $31,900 charge from the change in fair value of convertible promissory notes. For the first half of 2026, the net loss was $859,882 versus $651,416 in the prior-year period. Cash and cash equivalents fell sharply to $193,017 as of June 30, 2026 from $601,010 at December 31, 2025, and the company's stockholders' deficit deepened to ($1,779,301) from ($919,235), reflecting ongoing cash burn and no revenue generation.

• · The company has no revenue and relies on cash burn to fund operations.
• · Convertible promissory notes payable to related party increased to $867,700 as of June 30,2026 from $816,300 at December31,2025.
• · Warrant liability decreased to $1,415 as of June30,2026 from $11,323 at December31,2025.
• · Deferred offering costs of $1,204,631 were recorded as of June30,2026, up from $63,363 at December31,2025.
• · Net cash used in operating activities improved to $323,119 in first half 2026 from $572,647 in first half2025.
• · Stock-based compensation was negative $184 for first half2026, compared to positive $5,242 in first half2025.
• · The company had a working capital deficit of $1,779,301 as of June30,2026 (current liabilities of $3,188,329 vs current assets of $1,409,028).

17-09-2026

UPEXI, INC. (UPXI) filed its 10-K annual report for the fiscal year ended June 30, 2026, reporting total revenue of $24,998,028, up 58% from $15,811,345 in FY2025, driven by a surge in digital asset revenue from $985,009 to $17,429,206. However, the company recorded a massive net loss of $246,064,698 compared to a net loss of $13,684,209 in the prior year, primarily due to a $195,059,336 unrealized loss on digital assets and a sharp increase in general and administrative expenses to $26,398,877. The company's stockholders' equity turned negative to ($53,813,918) from $90,097,498, while working capital improved to $45,635,847 from $24,214,137.

• · Cost of revenue decreased 46.8% to $2,630,320 in FY2026 from $4,943,305 in FY2025.
• · Sales and marketing expenses decreased 27.6% to $2,898,473 from $4,001,094.
• · Distribution costs decreased 44.0% to $2,627,626 from $4,691,964.
• · Stock-based compensation surged to $21,895,814 from $2,356,862, an increase of 829%.
• · Realized loss on digital asset revenue conversion to USD was $4,931,791 in FY2026; none in FY2025.
• · Realized loss on sale of digital assets was $6,773,418 in FY2026; none in FY2025.
• · Impairment on assets from manufacturing shut down was $1,422,289 in FY2026; none in FY2025.
• · Impairment on acquired intangible assets was $750,000 in FY2026; none in FY2025.
• · Interest expense, net increased to $13,561,210 from $1,173,714.
• · Gain on extinguishment of debt was $10,288,342 in FY2026; none in FY2025.
• · Basic and diluted loss per share worsened to ($3.87) from ($1.73).
• · Basic weighted average shares outstanding increased to 63,539,613 from 7,914,268.
• · Total assets grew to $180,120,791 from $123,806,844.
• · Current liabilities increased to $71,130,418 from $32,563,906.
• · Convertible notes payable (long-term) were $162,442,056 as of June 30, 2026; none as of June 30, 2025.
• · Short-term treasury debt increased to $57,295,723 from $20,000,000.
• · Inventory, net decreased to $265,961 from $1,152,870.
• · Accounts receivable, net decreased to $97,244 from $157,515.
• · Property and equipment, net decreased to $208,044 from $2,052,573.
• · Goodwill decreased to $673,854 from $848,854.
• · Right-of-use asset, net decreased to $598,678 from $1,739,755.
• · Accounts payable decreased to $277,644 from $1,039,370.
• · Accrued compensation increased to $5,277,309 from $3,470,296.
• · Accrued liabilities increased to $1,675,521 from $356,064.
• · Accrued interest increased to $2,349,162 from $792,449.
• · Cash flows used in investing activities decreased to $30,623,761 from $99,293,083.
• · Cash flows provided by financing activities decreased to $54,383,404 from $110,029,860.
• · Common stock repurchases of 2,894,287 shares for $2,773,959 occurred in FY2026.

17-09-2026

Paramount Gold Nevada Corp. (PZG) filed its annual 10-K for the fiscal year ended June 30, 2026, reporting a net loss of $15.6M, up 72% from a $9.1M loss in FY2025. The company significantly strengthened its cash position to $9.9M from $1.4M, driven by $15.9M in financing activities including a $2.0M warrant private placement. However, total liabilities rose to $26.9M from $18.8M, primarily due to a $4.9M loss from the change in fair value of derivative liabilities and a new $2.8M warrant liability.

• · The company's accumulated deficit increased to $107.0M at June 30, 2026 from $91.4M at June 30, 2025.
• · Total liabilities rose to $26.9M from $18.8M, a 42.9% increase, driven by a new $2.8M warrant liability and a $4.9M increase in derivative liability.
• · Cash used in operating activities increased to $7.3M from $6.3M in the prior year.
• · The company issued 8,785,663 shares for financing in FY2026, raising $13.9M net, compared to 4,728,165 shares raising $2.4M in FY2025.
• · A $2.0M warrant private placement was completed in FY2026.
• · Exploration and development expenses increased 37.0% to $3.6M, while professional fees rose 66.8% to $0.7M and G&A expenses increased 57.8% to $1.2M.
• · Salaries and benefits decreased 17.4% to $1.4M, and directors' compensation fell 13.7% to $0.3M.
• · The derivative liability on the royalty convertible debenture nearly doubled to $8.9M from $4.1M.
• · The company has 86.1M shares outstanding at June 30, 2026, up from 75.4M a year earlier.
• · Outstanding RSUs remained nearly flat at 844,400 at June 30, 2026 versus 845,000 at June 30, 2025.
• · The weighted average grant date fair value of RSUs granted in FY2026 was $1.13, up from $0.35 in FY2025.
• · Interest expense remained essentially flat at $1.7M, with $1.5M paid in shares.
• · Mineral properties increased marginally to $49.2M from $49.1M.
• · The company's cash burn from operations increased 16.2% year-over-year.

17-09-2026

VITASPRING BIOMEDICAL CO. LTD. filed its 10-Q for the quarterly period ended July 31, 2026, reporting zero revenue for both the three and six months ended July 31, 2026 and 2025. The company's net loss widened to $155,817 for the quarter (from $110,845 in the prior year) and to $231,661 for the six-month period (from $191,386). Cash increased to $13,367 from $2,084 at January 31, 2026, but the company remains in a stockholders' deficit of $4,662,229, with total liabilities of $4,677,051 exceeding total assets of $14,822.

• · Total operating expenses increased to $161,817 for the quarter (from $99,067) and to $237,661 for the six-month period (from $168,214), driven primarily by higher professional fees.
• · Professional fees rose to $98,174 for the quarter (from $35,200) and to $110,374 for the six-month period (from $38,700).
• · Payroll expenses remained flat at $57,813 per quarter and $115,625 per six-month period.
• · General and administrative expenses decreased slightly to $5,830 for the quarter (from $6,054) and to $11,662 for the six-month period (from $13,889).
• · The company recorded a non-cash reclassification of $2,411,000 from accounts payable - related party to loan payable - related party during the six months ended July 31, 2026.
• · Equipment and vehicle, net was fully depreciated/ impaired to $0 as of July 31, 2026 (from $4,149 at January 31, 2026).
• · Net cash provided by operating activities was $11,283 for the six months ended July 31, 2026, compared to net cash used in operating activities of $1,973 in the prior year period.
• · The company had no revenue and continues to rely on related party advances and loans to fund operations.

17-09-2026

VanEck BNB ETF filed its first annual report (10-K) for the period from inception (April 22, 2026) to June 30, 2026. The trust reported a net decrease in net assets from operations of $309,637, driven by a $308,925 unrealized loss on its BNB investment and a $712 net investment loss. Net assets ended at $2,140,751 with a NAV per share of $21.41, down from $25.00 at inception, reflecting a total return of -14.36%.

• · The trust is not actively managed and does not attempt to protect against or take advantage of BNB price fluctuations.
• · Each delivery or sale of BNB to pay expenses is a taxable event to beneficial owners, potentially creating tax liability without a distribution.
• · No BNB was sold or redeemed during the period; all BNB was purchased at inception.
• · The trust's expense ratio was 0.39% (annualized) for the period.

17-09-2026

CTT Pharmaceutical Holdings, Inc. reported a net loss of $99,908 for the six months ended June 30, 2026, compared to a net loss of $90,273 in the same period of 2025, representing a 10.7% increase in losses. Total assets declined sharply from $86,168 to $67,434, driven by a cash burn that reduced cash from $15,359 to just $31, while related-party payables increased from $12,204 to $21,949. The company raised only $10,801 from share sales in 2026 versus $79,999 in 2025, indicating significantly reduced financing activity.

• · Intangible assets, net decreased from $70,809 to $67,403, primarily due to amortization of $3,406.
• · Accumulated amortization on intangibles increased from $56,951 to $60,357.
• · Deferred patent costs remained unchanged at $4,313.
• · Patents and trademarks balances were unchanged at $109,883 and $13,564 respectively.
• · The company had no preferred stock issued or outstanding.
• · Basic and diluted loss per share was $0.00 for both periods.
• · Cash used in operating activities improved to $26,129 from $47,783, a 45.3% reduction.
• · Accrued interest increased by $628 in 2026 vs $470 in 2025.
• · Changes in accounts payable and accrued expenses provided $9,745 in 2026 vs a use of $21,300 in 2025.